Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05916963

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

Conditions: Kidney Stone

Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 374
Sponsor: University Hospital, Tours

Location: CHU d'Angers Angers

Summary

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Eligibility Criteria

Inclusion Criteria: * Patients ≥ 18 years old and \< 80 years old * With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser * Participants covered by or entitled to social security * Written informed consent obtained from the participant * Ability for participant to comply with the requirements of the study Exclusion Criteria: * Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship) * Contra-indication to Furosemide: * Hyper-sensitivity to the active substance or one of the excipients * Hyper-sensitivity to Sulfonamide * Renal failure with oligo-anuria refractory to Furosemide * Hypokalemia \< 3,5 mmol/L * Severe hyponatremia * Hypovolemia with or without hypotension or dehydration * Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy * Patient having Furosemide as usual treatment * Patient requiring an injection of Aminoside or Vancomycin before or during the procedure * Participation in other interventional research with an investigational drug or medical device

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05916963). StuddyBuddy aggregates publicly available trial information.